**Table S1:** E-test results of the wildtype and ΔltaS strain of *S. mitis* ATCC 49456 (SM61)

| Strain     | Antimicrobial Agent | MIC Median and Range (μg/mL) | S/R |
|------------|---------------------|------------------------------|-----|
| Wildtype   | Ampicillin          | 0.023 (≤0.016–≤0.023)        | S   |
|            | Daptomycin          | 0.1575 (0.094–≤0.25)         | NA  |
|            | Vancomycin          | 0.5 (0.38–≤0.75)             | S   |
|            | Gentamycin          | 1.0 (0.75–≤1.0)              | S   |
|            | Linezolid           | 0.38 (0.38–≤1.0)             | S   |
|            | Cefazolin           | 0.19 (0.125–≤0.19)           | S   |
| ΔltaS      | Ampicillin          | 0.032 (0.023–≤0.032)         | S   |
|            | Daptomycin          | 0.142 (0.094–≤0.19)          |     |
|            | Vancomycin          | 0.5 (0.5–0.5)                |     |
|            | Gentamycin          | 1.0 (1.0–1.0)                |     |
|            | Linezolid           | 0.5 (0.25–≤0.5)              |     |
|            | Cefazolin           | 0.25 (0.19–≤0.25)            |     |

*a Abbreviations: S, susceptible; R, resistant; NA, not applicable.

*b The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. [http://www.eucast.org](http://www.eucast.org)*

*c No breakpoint has been established for daptomycin.

*d CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.*